Breaking Down Anshan Hifichem Co., Ltd. Financial Health: Key Insights for Investors

Curious how Anshan Hifichem's recent figures translate into investment merit? The company posted a headline revenue of CNY 1.57 billion in 2024 (up 28.75% from CNY 1.22 billion) and generated CNY 365 million in Q1 2025 toward a TTM revenue of CNY 1.61 billion, while maintaining a gross margin of 31.77% and revenue per employee of CNY 724,806-signals of scale and operational efficiency; profitability surged to a net income of CNY 124.93 million in 2024 (a 1,035.48% year-on-year jump) with a TTM net margin of 7.97% and EPS of CNY 0.19, even as market expectations push valuation metrics high (trailing P/E as reported at 65.29 and forward P/E 22.73, EV/EBITDA 22.49, EV/FCF negative), and the balance sheet shows a debt-to-equity ratio of 0.57, total assets of CNY 3.89 billion, total liabilities of CNY 965.11 million and current/quick ratios of 1.33/0.82-together with supplier concentration (65% from three suppliers), <10% export exposure, and production utilization near 75% these metrics outline both risk vectors and growth levers; read on to unpack revenue trends, profitability ratios, liquidity, valuation nuances and the catalysts that could reshape investor outcomes.

Anshan Hifichem Co., Ltd. (300758.SZ) - Revenue Analysis

Anshan Hifichem reported significant topline momentum in 2024 and early 2025, driven primarily by domestic demand and improved unit economics.

• 2024 revenue: CNY 1.57 billion (up 28.75% vs. 2023 CNY 1.22 billion)
• Revenue per employee: CNY 724,806 - implying ~2,166 employees (1,570,000,000 / 724,806)
• Gross margin (TTM): 31.77% - indicates maintained profitability despite cost pressures
• Q1 2025 revenue: CNY 365 million; contributes to TTM revenue of CNY 1.61 billion
• 3-year average revenue growth: 4.20% per year
• Geographic mix: >90% China, international sales <10%

Key implications for investors:

• High revenue-per-employee suggests operational efficiency relative to peers in specialty chemicals.
• Gross margin of 31.77% gives a buffer vs. input-cost volatility but should be monitored if international expansion pushes pricing pressure.
• Concentration in China (>90% revenue) raises market/geopolitical concentration risk while limiting foreign-currency diversification.
• Recent acceleration (2024 strong growth and Q1 2025) may reflect product mix shifts, pricing, or volume recovery; verify sustainability via order backlog and margin trends.

For broader context on the company's background and business model, see Anshan Hifichem Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Anshan Hifichem Co., Ltd. (300758.SZ) - Profitability Metrics

• Net income (2024): CNY 124.93 million - up 1,035.48% vs. prior year (prior-year net income ≈ CNY 11.00 million).
• Trailing twelve months (TTM) net profit margin: 7.97%.
• Return on equity (ROE): 4.32%.
• Return on assets (ROA): 2.42%.
• Return on invested capital (ROIC): 3.10%.
• TTM earnings per share (EPS): CNY 0.19; P/E ratio: 65.29.

• Interpreting the jump in net income: combination of revenue growth, margin improvement, one-off items, or tax/expense reversals should be reviewed in filings.
• Profitability levels (ROE/ROA/ROIC) are modest relative to the sharp net income increase-monitor sustainability.
• High P/E (65.29) versus EPS CNY 0.19 signals elevated investor expectations; valuation sensitivity to earnings variability is high.

Anshan Hifichem Co., Ltd. (300758.SZ) - Debt vs. Equity Structure

• Leverage profile: Debt-to-equity of 0.57 signals a conservative-to-moderate reliance on debt financing relative to equity, keeping financial risk manageable.
• Interest sustainability: An interest coverage ratio of 3.17 indicates operating earnings are roughly three times interest expense, providing a comfortable cushion but not room for major margin deterioration.
• Liquidity dynamics: Current ratio 1.33 shows adequate short-term coverage; quick ratio 0.82 highlights dependence on inventory turnover to meet near-term obligations.
• Balance sheet strength: Total assets of CNY 3.89 billion vs. total liabilities CNY 965.11 million imply a substantial equity buffer and solvency headroom.

Anshan Hifichem Co., Ltd. (300758.SZ) - Liquidity and Solvency

• Current ratio: 1.33 - sufficient current assets to cover short-term liabilities, providing near-term liquidity comfort.
• Quick ratio: 0.82 - below 1.0, signaling reliance on inventory conversion to meet short-term obligations.
• Interest coverage ratio: 3.17 - operating income covers interest expenses roughly 3.2 times, indicating reasonable capacity to service debt but limited cushion against earnings pressure.
• Debt-to-equity ratio: 0.57 - moderate leverage, with long-term financing not overly aggressive relative to shareholders' equity.
• Net change in cash (latest quarter): -CNY 30.40 million - a reduction in cash reserves that may reflect working capital use, capex, or financing timing.

• Working capital: With a current ratio >1 but quick ratio <1, the company appears to rely on inventory turnover to meet short-term needs; inventory management and receivables collection are critical monitoring points.
• Debt service: An interest coverage of 3.17 and a debt-to-equity of 0.57 indicate the company can service its debt under current operating conditions, but margins or EBITDA declines would reduce the safety margin.
• Balance sheet strength: CNY 3.89 billion in assets versus CNY 965.11 million in liabilities provides a solid asset base and equity buffer supporting solvency.
• Cash flow watch: The quarterly cash decline of CNY 30.40 million warrants attention to operating cash generation and capital spending plans to ensure liquidity remains sufficient.

Anshan Hifichem Co., Ltd. (300758.SZ) - Valuation Analysis

• Trailing P/E: 73.66 - implies investors are paying a high multiple for historical earnings.
• Forward P/E: 22.73 - suggests the market anticipates substantial earnings growth over the next 12 months.
• P/S ratio: 3.67 - investors pay a premium per unit of revenue relative to many peers.
• P/B ratio: 2.87 - stock trades meaningfully above book value, reflecting expected return on equity or intangible asset valuation.
• EV/EBITDA: 22.49 - valuation relative to operating profitability is elevated, consistent with growth expectations.
• EV/FCF: -68.24 - negative free cash flow causes a negative multiple, signaling potential cash-generation issues or heavy reinvestment.
• Market capitalization: CNY 5.35 billion (↑32.12% over the past 12 months, as of 2025-09-29).

• Valuation tension: the gap between trailing and forward P/E (73.66 vs. 22.73) signals that the market expects a marked recovery/acceleration in earnings; if execution lags, downside risk is substantial.
• Cash flow caution: EV/FCF at -68.24 is a red flag - negative free cash flow reduces margin for error and increases reliance on financing or equity issuance to fund growth.
• Relative premium: P/S 3.67 and P/B 2.87 place the stock above many commodity/chemical peers; justification hinges on durable revenue growth, margin expansion, or differentiation.
• Market sentiment: a 32.12% market-cap rise to CNY 5.35 billion as of 2025-09-29 demonstrates investor bullishness, but elevated multiples heighten sensitivity to missed forecasts.

Anshan Hifichem Co., Ltd. (300758.SZ) - Risk Factors

• Supplier concentration: ~65% of raw materials sourced from three suppliers, creating significant single-source risk and limited bargaining leverage.
• Geographic concentration: <10% of total sales from overseas markets, restricting revenue diversification and exposure to faster-growing international end-markets.
• Capacity utilization: production running at ~75% utilization, indicating constrained ability to scale quickly to meet demand spikes without incremental capital expenditure.
• Input-price volatility: petrochemical-derived raw materials surged ~25% in 2022, materially pressuring margins and working capital.
• Margin compression: net profit margin declined to 12% from 15% year-over-year, reflecting sensitivity to raw-material inflation and cost passthrough limits.

• Cash-flow & working capital risks: spikes in raw-material costs increase inventory value and may strain short-term liquidity if pass-through to customers is delayed.
• Operational capex risk: addressing 75% utilization and supply diversification may require capital investment, affecting free cash flow and return on invested capital.
• Concentration counterparty risk: dependence on a few suppliers elevates the probability that a single disruption (logistics, regulatory, insolvency) materially impacts production.

Anshan Hifichem Co., Ltd. (300758.SZ) - Growth Opportunities

• Sustainable product portfolio: eco-friendly product revenues rose 25% over two years and represented 18% of total revenue in 2023 - signaling market traction and premium positioning.
• Strategic partnerships: three industry collaborations targeting niche specialty chemicals are projected to add CNY 50 million in revenue in 2023 from those markets.
• R&D commitment: R&D spend reached approximately CNY 50 million in 2023, about 5% of annual revenue, supporting product pipeline expansion and differentiation.
• Operational technology: AI-driven process optimization delivered a 20% reduction in production costs, improving gross-margin potential.
• Logistics automation: robotics investments lifted order fulfillment rates by 15%, reducing lead times and enhancing customer service metrics.
• ESG alignment: formal commitment to the United Nations Global Compact strengthens the company's sustainability credentials and appeal to ESG-focused buyers and investors.

• Near-term growth catalysts: commercialization of R&D-derived specialty products, scale-up of eco-product lines (target: increase eco-product share beyond 18%), and monetization of partnership pipelines (CNY 50M uplift realized in 2023).
• Margin and efficiency drivers: sustained AI usage and expanded robotics deployment can extend production-cost savings beyond 20% and further reduce logistics-related wastage.
• Investor-relevant KPIs to monitor: eco-product revenue share, R&D-to-revenue ratio, realized revenue from partnerships, production cost per unit, order fulfillment rate, and progress on UN Global Compact initiatives.